Alnylam's RNAi obesity drug ALN-2232 heads toward first human weight-loss data
A Phase 1/2 trial testing whether silencing ACVR1C can cut body weight is recruiting toward a primary completion date in April 2027, well past the H2-2026 window Alnylam has flagged for initial results.
Executive Summary
- Alnylam has told investors to expect data in the second half of 2026 from its first human trial of an RNAi drug designed to silence a signaling target implicated in fat-tissue biology, but the trial itself is still recruiting and its registered completion date falls almost a year past that window.
- The study's structure, a safety-focused cohort feeding into two dose-ranging efficacy cohorts that both track body-weight change, means any interim disclosure would be an early tolerability and target-engagement signal, not a comparative efficacy result.
- The obesity field is currently defined by incretin-pathway drugs from Novo Nordisk and Eli Lilly; an RNAi approach aimed at a different signaling target has no direct precedent to be measured against, for better or worse.
- A credible early readout would mark Alnylam's first extension of its RNAi platform beyond liver- and rare-disease-focused programs into a cardiometabolic indication with a much larger patient population.
The catalyst
Alnylam said in its first-quarter 2026 earnings release that it had initiated a Phase 1 study of ALN-2232, describing it as the company's first adipose-tissue-targeted program for obesity and weight management, and that it expects to announce trial results in the second half of 2026. The trial, registered as NCT07463846, is a Phase 1/Phase 2 study evaluating ALN-2232 in adults with a body mass index between 30 and 40 kg/m^2 and HbA1c below 6.5%. Alnylam+1Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressApr 30, 2026A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
Trial design
The study enrolls a target of 156 participants across three parts under a randomized, placebo-controlled design. Part A measures the frequency of adverse events and pharmacokinetic parameters including plasma concentration and urinary excretion; Parts B and C both measure percent change from baseline in body weight, along with body fat mass and lean mass. The trial carries three primary endpoints and nine secondary endpoints across the three parts. NCT07463846A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846
Timing mismatch
The trial began recruiting on March 2, 2026, and its registered primary completion date is April 27, 2027, ten months later than the guided H2-2026 disclosure window that runs from July 1 to December 31, 2026. That primary completion date itself moved earlier: the registry shows it pulled in from February 1, 2028 to April 27, 2027, a change logged on May 14, 2026. Any 2026 disclosure would necessarily draw on an interim look at Part A safety data or early dosing cohorts rather than a completed trial. NCT07463846+1A Study to Evaluate ALN-2232 in Participants With ObesityNCT07463846Alnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressApr 30, 2026
Competitive landscape
No trial sharing ACVR1C as a target or an RNAi silencing mechanism was found active in obesity, leaving ALN-2232 without a direct mechanistic comparator. The active obesity field instead centers on GLP-1 receptor agonists, including ongoing Phase 3 and Phase 4 programs for semaglutide and tirzepatide, and Eli Lilly's Phase 3 retatrutide, all of which work through the incretin pathway rather than adipose-tissue signaling. That leaves ALN-2232's mechanism mechanistically isolated within the current obesity landscape, with the nearest comparators sharing only the indication and none sharing the target or modality.
Platform context
The program extends Alnylam's RNAi platform, already commercialized in AMVUTTRA and ONPATTRO for transthyretin amyloidosis, into a cardiometabolic indication for the first time. Alnylam Chief Executive Officer Yvonne Greenstreet said the company was "initiating a Phase 1 study for our first adipose-targeted program for obesity and weight management" as part of progress toward its 2030 pipeline goals. AlnylamAlnylam Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Period ProgressApr 30, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.